Last 12 months
Inside the activity.
0 purchase rows · 34 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 7 |
| Jun 2026 | 0 | 9 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2021 Filed Mar 2, 2021 21:15 UTC |
Colangelo DominickDirector · President and CEO
|
SaleCommon Stock | 1,548 | $48.47 | $75,031.56 |
DisclosureSEC source: 0001593968-21-000706 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,647 F1 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:13 UTC |
Colangelo DominickDirector · President and CEO
|
GrantRestricted Stock Unit · Derivative | 35,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000545 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,750 Underlying: Common Stock · 35,750 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2022. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:13 UTC |
Colangelo DominickDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 1,945 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000545 · primary_01.xml · derivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,945 Underlying: Common Stock · 1,945 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:13 UTC |
Colangelo DominickDirector · President and CEO
|
GrantStock Option (right to buy) · Derivative | 298,055 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000545 · primary_01.xml · derivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,055 Underlying: Common Stock · 298,055 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:10 UTC |
Flynn Sean C.VP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 56,110 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000544 · primary_01.xml · derivative · entry 3 Flynn Sean C. · CIK 0001801993 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,110 Underlying: Common Stock · 56,110 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:10 UTC |
Flynn Sean C.VP, General Counsel
|
GrantRestricted Stock Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000544 · primary_01.xml · derivative · entry 2 Flynn Sean C. · CIK 0001801993 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2022. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:10 UTC |
Flynn Sean C.VP, General Counsel
|
GrantStock Option (right to buy) · Derivative | 3,890 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000544 · primary_01.xml · derivative · entry 1 Flynn Sean C. · CIK 0001801993 · VP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,890 Underlying: Common Stock · 3,890 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:07 UTC |
Hopper Jonathan MarkChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000542 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2022. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:07 UTC |
Hopper Jonathan MarkChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 57,177 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000542 · primary_01.xml · derivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,177 Underlying: Common Stock · 57,177 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:07 UTC |
Hopper Jonathan MarkChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 2,823 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000542 · primary_01.xml · derivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,823 Underlying: Common Stock · 2,823 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:09 UTC |
Halpin MichaelChief Operating Officer
|
GrantRestricted Stock Unit · Derivative | 11,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000543 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 11,250 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 19, 2022. The remaining RSUs will vest in annual installments on February 19, 2023, February 19, 2024, and February 19, 2025, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:09 UTC |
Halpin MichaelChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 98,055 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000543 · primary_01.xml · derivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,055 Underlying: Common Stock · 98,055 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:09 UTC |
Halpin MichaelChief Operating Officer
|
GrantStock Option (right to buy) · Derivative | 1,945 | $0.00 Strike: $51.40 | $0.00 |
DisclosureSEC source: 0001593968-21-000543 · primary_01.xml · derivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,945 Underlying: Common Stock · 1,945 shares Expires 2031-02-19 F1 · derivative.exercise_date: These options shall begin vesting on February 19, 2021 and shall vest and become exercisable in equal quarterly installments over the course of the following four (4) year period. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,625 | $49.23 | $79,998.75 |
DisclosureSEC source: 0001593968-21-000438 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,875 Underlying: Common Stock · 1,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 738 | $49.23 | $36,331.74 |
DisclosureSEC source: 0001593968-21-000438 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,633 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:17 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 1,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000438 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,500 | $49.23 | $369,225.00 |
DisclosureSEC source: 0001593968-21-000437 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 7,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 3,267 | $49.23 | $160,834.41 |
DisclosureSEC source: 0001593968-21-000437 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,195 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:16 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000437 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,462 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:12 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 3,500 | $49.23 | $172,305.00 |
DisclosureSEC source: 0001593968-21-000435 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 3,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:12 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 1,516 | $49.23 | $74,632.68 |
DisclosureSEC source: 0001593968-21-000435 · primary_01.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,437 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 11, 2021 Filed Feb 12, 2021 21:12 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000435 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 11, 2020. The remaining RSUs will vest in annual installments on February 11, 2022, February 11, 2023, and February 11, 2024, respectively. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:26 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 1,875 | $47.18 | $88,462.50 |
DisclosureSEC source: 0001593968-21-000364 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:26 UTC |
Halpin MichaelChief Operating Officer
|
Tax withholdingCommon Stock | 892 | $47.18 | $42,084.56 |
DisclosureSEC source: 0001593968-21-000364 · primary_01.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,453 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:26 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 1,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000364 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:25 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 650 | $47.18 | $30,667.00 |
DisclosureSEC source: 0001593968-21-000363 · primary_01.xml · derivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Underlying: Common Stock · 650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:25 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Tax withholdingCommon Stock | 264 | $47.18 | $12,455.52 |
DisclosureSEC source: 0001593968-21-000363 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,746 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:25 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000363 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,010 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:24 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 6,938 | $47.18 | $327,334.84 |
DisclosureSEC source: 0001593968-21-000362 · primary_01.xml · derivative · entry 3 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,875 Underlying: Common Stock · 6,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F4 · derivative.exercise_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. F5 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:24 UTC |
Colangelo DominickDirector · President and CEO
|
Tax withholdingCommon Stock | 3,078 | $47.18 | $145,220.04 |
DisclosureSEC source: 0001593968-21-000362 · primary_01.xml · nonDerivative · entry 2 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,962 F2 · shares: These shares were withheld by the Issuer to satisfy the tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 06, 2021 Filed Feb 8, 2021 21:24 UTC |
Colangelo DominickDirector · President and CEO
|
Exercise / conversionCommon Stock | 6,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000362 · primary_01.xml · nonDerivative · entry 1 Colangelo Dominick · CIK 0001313403 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of common stock were acquired by the Reporting person as a result of the vesting of RSUs granted to the Reporting Person on February 6, 2019. The remaining RSUs will vest in annual installments on February 6, 2022, and February 6, 2023, respectively. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:16 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 9,168 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001593968-21-000196 · primary_01.xml · derivative · entry 3 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,168 Underlying: Common Stock · 9,168 shares Expires 2031-01-25 F1 · derivative.exercise_date: These options shall begin vesting on January 25, 2021 and shall vest and become exercisable on January 25, 2022, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:16 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-21-000196 · primary_01.xml · derivative · entry 2 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation. F3 · derivative.exercise_date: These RSUs vest in four equal installments with the initial vesting of RSUs granted to the Reporting Person on March 31, 2021. The remaining RSUs will vest on June 30, 2021, September 30, 2021, and December 31, 2021, respectively. F4 · derivative.expiration_date: No expiration date for this type of award. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 21:16 UTC |
Mara Joseph Anthony JrChief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 150,832 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001593968-21-000196 · primary_01.xml · derivative · entry 1 Mara Joseph Anthony Jr · CIK 0001841148 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,832 Underlying: Common Stock · 150,832 shares Expires 2031-01-25 F1 · derivative.exercise_date: These options shall begin vesting on January 25, 2021 and shall vest and become exercisable on January 25, 2022, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter. Read SEC document |
| December 31, 2020 Filed Jan 28, 2021 21:20 UTC |
Halpin MichaelChief Operating Officer
|
GrantCommon Stock | 191 | $16.64 | $3,178.81 |
DisclosureSEC source: 0001593968-21-000238 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,470 F1 · shares: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 18,264 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · derivative · entry 9 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,736 Underlying: Common Stock · 18,264 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · derivative · entry 8 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 20,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $10.95 | $0.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · derivative · entry 7 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 5,000 shares Expires 2028-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 11,709 | $26.61 | $311,541.36 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 6 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,360 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 20,000 | $10.95 | $219,000.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 5 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,069 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 7,526 | $26.61 | $200,244.28 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 4 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,069 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 18,264 | $10.95 | $199,990.80 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 3 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
SaleCommon Stock | 5,000 | $26.27 | $131,373.50 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 2 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,331 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:11 UTC |
Hopper Jonathan MarkChief Medical Officer
|
Exercise / conversionCommon Stock | 5,000 | $10.95 | $54,750.00 |
DisclosureSEC source: 0001593968-20-002403 · primary_01.xml · nonDerivative · entry 1 Hopper Jonathan Mark · CIK 0001626325 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,331 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:10 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $2.65 | $0.00 |
DisclosureSEC source: 0001593968-20-002402 · primary_01.xml · derivative · entry 3 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,063 Underlying: Common Stock · 30,000 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: These options, representing the right to purchase 135,000 shares, became exercisable on April 10, 2018, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:10 UTC |
Halpin MichaelChief Operating Officer
|
SaleCommon Stock | 30,000 | $26.28 | $788,400.00 |
DisclosureSEC source: 0001593968-20-002402 · primary_01.xml · nonDerivative · entry 2 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,279 F2 · acquired: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:10 UTC |
Halpin MichaelChief Operating Officer
|
Exercise / conversionCommon Stock | 30,000 | $2.65 | $79,500.00 |
DisclosureSEC source: 0001593968-20-002402 · primary_01.xml · nonDerivative · entry 1 Halpin Michael · CIK 0001778858 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.76 | $0.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · derivative · entry 5 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC |
ZERBE ROBERT L MDDirector
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · derivative · entry 4 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2025-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options, representing the right to purchase a total of 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015 and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:09 UTC |
ZERBE ROBERT L MDDirector
|
SaleCommon Stock | 17,500 | $23.55 | $412,125.00 |
DisclosureSEC source: 0001593968-20-002243 · primary_01.xml · nonDerivative · entry 3 ZERBE ROBERT L MD · CIK 0001220363 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,795 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.